
Disc Medicine, Inc.: shareholders and insiders
Price
$75.14
November 20, 2026Market cap $3.4B
What Ploutos Investor adds for Disc Medicine
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors, from their own Form 4 filings.
Reading the newest filings from the SEC. This part fills in on its own in a few seconds.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- FMRwith 1 more personShare of class12.8%
- Ai Dmiwith 3 more personsShare of class6.60%
- RA Capital Management, L.P.with 3 more personsShare of class5.90%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| FMRwith 1 more person | 12.8% | 4.88M | Aug 6, 20265 filings since Feb 12, 2025 | 13G/A | |
| Ai Dmiwith 3 more persons | 6.60% | 2.94M | Oct 26, 20263 filings since Mar 3, 2025 | 13D/A | |
| RA Capital Management, L.P.with 3 more persons | 5.90% | 2.23M | Jan 7, 2026 | 13G |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
Ai Dmi6.6%From the filing of Oct 22, 2025
The disclosure in Item 4 to the Schedule is hereby supplemented by adding the following at the end thereof: On October 20, 2025, the Issuer entered into an underwriting agreement (the "Underwriting Agreement") with AI DMI LLC as a selling stockholder and Jefferies LLC, Leerink Partners LLC, Morgan Stanley & Co. LLC and Cantor Fitzgerald & Co. (the "Representatives"), as representatives of the several underwriters listed on Schedule I thereto (the "Underwriters"), related to an underwritten offering (the "Offering"), pursuant to which (i) the Issuer issued and sold (a) 2,619,049 shares of Common Stock at a price to the public of $84.00 per share and (b) in lieu of Common Stock to certain…
From the filing of Oct 22, 2025
Fell to 5% or less (6)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- Atlas Venture Fund X, L.P.13D2.20%Dec 17, 202513D/A
- Frazier Life Sciences Public Fund, L.P.3.00%Aug 14, 202513G/A
- Wellington Management Group LLP4.10%Aug 12, 202513G/A
- Paradigm BioCapital Advisors LP3.50%May 15, 202513G/A
- Orbimed Advisors13D4.50%Mar 12, 202513D/A
- Bain Capital Life Sciences Opportunities III, LP3.30%Feb 14, 202513G/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter-37%
- Millennium Mgmt (Englander)In the quarter-50%
- D.E. ShawIn the quarter+606%
- AQR CapitalIn the quarter-13%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 131.3K | -37% | $8.6M | 0.00% |
| Millennium Mgmt (Englander) | 53.2K | -50% | $3.5M | 0.00% |
| D.E. Shaw | 42.5K | +606% | $2.8M | 0.00% |
| AQR Capital | 8,608 | -13% | $600.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 16.4% of its shares outstanding were held short, +2.6% since the report before.
- Shares held short
- 7.46M
- 16.4%
- Since the report before7.27M on Sep 30, 2026
- +2.6%
- 10.6
- 701.3K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 93%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 1.11M
- Nov 15, 2023: Shares held short 1.20M
- Nov 30, 2023: Shares held short 1.31M
- Dec 15, 2023: Shares held short 1.26M
- Dec 29, 2023: Shares held short 1.15M
- Jan 12, 2024: Shares held short 1.23M
- Jan 31, 2024: Shares held short 1.32M
- Feb 15, 2024: Shares held short 1.21M
- Feb 29, 2024: Shares held short 1.19M
- Mar 15, 2024: Shares held short 1.26M
- Mar 28, 2024: Shares held short 1.86M
- Apr 15, 2024: Shares held short 1.91M
- Apr 30, 2024: Shares held short 1.67M
- May 15, 2024: Shares held short 1.97M
- May 31, 2024: Shares held short 1.88M
- Jun 14, 2024: Shares held short 2.00M
- Jun 28, 2024: Shares held short 1.58M
- Jul 15, 2024: Shares held short 1.64M
- Jul 31, 2024: Shares held short 1.36M
- Aug 15, 2024: Shares held short 1.35M
- Aug 30, 2024: Shares held short 1.48M
- Sep 13, 2024: Shares held short 1.40M
- Sep 30, 2024: Shares held short 1.59M
- Oct 15, 2024: Shares held short 1.48M
- Oct 31, 2024: Shares held short 1.63M
- Nov 15, 2024: Shares held short 1.64M
- Nov 29, 2024: Shares held short 1.63M
- Dec 13, 2024: Shares held short 1.66M
- Dec 31, 2024: Shares held short 1.77M
- Jan 15, 2025: Shares held short 2.04M
- Jan 31, 2025: Shares held short 2.17M
- Feb 14, 2025: Shares held short 2.48M
- Feb 28, 2025: Shares held short 2.32M
- Mar 14, 2025: Shares held short 2.24M
- Mar 31, 2025: Shares held short 2.42M
- Apr 15, 2025: Shares held short 2.73M
- Apr 30, 2025: Shares held short 3.21M
- May 15, 2025: Shares held short 3.23M
- May 30, 2025: Shares held short 3.10M
- Jun 13, 2025: Shares held short 3.20M
- Jun 30, 2025: Shares held short 3.07M
- Jul 15, 2025: Shares held short 2.83M
- Jul 31, 2025: Shares held short 2.26M
- Aug 15, 2025: Shares held short 2.43M
- Aug 29, 2025: Shares held short 2.10M
- Sep 15, 2025: Shares held short 2.24M
- Sep 30, 2025: Shares held short 2.64M
- Oct 15, 2025: Shares held short 2.69M
- Oct 31, 2025: Shares held short 2.87M
- Nov 14, 2025: Shares held short 3.02M
- Nov 28, 2025: Shares held short 2.59M
- Dec 15, 2025: Shares held short 2.46M
- Dec 31, 2025: Shares held short 3.79M
- Jan 15, 2026: Shares held short 4.28M
- Jan 30, 2026: Shares held short 4.10M
- Feb 13, 2026: Shares held short 3.41M
- Feb 27, 2026: Shares held short 4.27M
- Mar 13, 2026: Shares held short 4.50M
- Mar 31, 2026: Shares held short 5.46M
- Apr 15, 2026: Shares held short 5.24M
- Apr 30, 2026: Shares held short 5.54M
- May 15, 2026: Shares held short 5.67M
- May 29, 2026: Shares held short 6.00M
- Jun 15, 2026: Shares held short 6.01M
- Jun 30, 2026: Shares held short 6.36M
- Jul 15, 2026: Shares held short 7.29M
- Jul 31, 2026: Shares held short 7.39M
- Aug 14, 2026: Shares held short 7.34M
- Aug 31, 2026: Shares held short 7.37M
- Sep 15, 2026: Shares held short 7.21M
- Sep 30, 2026: Shares held short 7.27M
- Oct 15, 2026: Shares held short 7.46M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading43.7% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 43.7% of the shares in the reported trades were short sales, against 48.5% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 43.7%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 48.5%
- Change
- -4.8 pts
- Short sales a dayon average, of 296.5K shares
- 129.5K
- More than atof 3,666 US-listed companies, same days
- 29%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 64.5%
- Oct 15, 2026: Short sales 54.1%
- Oct 16, 2026: Short sales 80.8%
- Oct 19, 2026: Short sales 54.1%
- Oct 20, 2026: Short sales 41.1%
- Oct 21, 2026: Short sales 40%
- Oct 22, 2026: Short sales 51.7%
- Oct 23, 2026: Short sales 44.5%
- Oct 26, 2026: Short sales 43.2%
- Oct 27, 2026: Short sales 40.1%
- Oct 28, 2026: Short sales 49.6%
- Oct 29, 2026: Short sales 44.4%
- Oct 30, 2026: Short sales 54.1%
- Nov 2, 2026: Short sales 39.6%
- Nov 3, 2026: Short sales 44.9%
- Nov 4, 2026: Short sales 34.8%
- Nov 5, 2026: Short sales 36.7%
- Nov 6, 2026: Short sales 27%
- Nov 9, 2026: Short sales 33.6%
- Nov 10, 2026: Short sales 37%
- Nov 11, 2026: Short sales 53.7%
- Nov 12, 2026: Short sales 65.2%
- Nov 13, 2026: Short sales 58.1%
- Nov 16, 2026: Short sales 49.7%
- Nov 17, 2026: Short sales 49.2%
- Nov 18, 2026: Short sales 47.5%
- Nov 19, 2026: Short sales 39.1%
- Nov 20, 2026: Short sales 52.9%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.65%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.51%
- IBBiShares Biotechnology ETFWeight in the fund0.16%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.12%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.07%
- IWMiShares Russell 2000 ETFWeight in the fund0.07%
- DFASDimensional U.S. Small Cap ETFWeight in the fund0.06%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.05%
- VXFVanguard Extended Market Index FundWeight in the fund0.03%
- VHTVanguard Health Care Index FundWeight in the fund0.03%
18 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 168
- Q4 2025: Managers 197
- Q1 2026: Managers 204
- Q2 2026: Managers 216
Institutional investors by quarter
The fund managers holding IRON, quarter by quarter, from Q4 2022 to Q2 2025, 11 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 216 managers held 43.15M shares, worth $3.2B. During the quarter 39 opened a position, 27 closed one, 74 added and 60 trimmed.
The largest holders, Q2 2026
- FMRIn the quarter-12%
- BlackRockIn the quarter+8.5%
- Ra Capital ManagementIn the quarter
- JPMorgan ChaseIn the quarter+37%
- Price T Rowe AssociatesIn the quarter+21%
- Wellington Management GroupIn the quarter+0.3%
- State StreetIn the quarter-2.9%
- Vestal Point CapitalIn the quarter+121%
- Atlas Venture Life Science AdvisorsIn the quarter
- Vanguard Capital ManagementIn the quarter-0.5%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| FMR | 4.89M | -12% | $358M |
| BlackRock | 2.47M | +8.5% | $181M |
| Ra Capital Management | 2.45M | $179M | |
| JPMorgan Chase | 1.88M | +37% | $140M |
| Price T Rowe Associates | 1.88M | +21% | $137M |
| Wellington Management Group | 1.74M | +0.3% | $127M |
| State Street | 1.65M | -2.9% | $121M |
| Vestal Point Capital | 1.55M | +121% | $113M |
| Atlas Venture Life Science Advisors | 1.51M | $111M | |
| Vanguard Capital Management | 1.37M | -0.5% | $100M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Disc Medicine's filings show?
Who buys and sells is one part of Disc Medicine's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Which well-known managers hold IRON?
4 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $8.6M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.